Form 4: Processa Pharmaceuticals Executive Patrick Lin Reports Stock Transactions
SEC Form 4 Filing
Patrick Lin, Chief Business Strategy Officer of Processa Pharmaceuticals, reports the acquisition and disposal of common stock on April 1, 2025.
Summary
- On April 1, 2025, Patrick Lin, Chief Business Strategy Officer of Processa Pharmaceuticals, engaged in transactions involving the company's common stock.
- Lin acquired 14,482 shares through the vesting of restricted shares.
- Lin disposed of 4,814 shares to cover tax obligations at a price of $0.412 per share.
- Following these transactions, Lin directly owns 38,727 shares and indirectly owns 43,500 shares through the Lin Family Trust dated Feb 4, 2024.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, as required by the SEC. It provides transparency into the trading activities of key personnel and their holdings in the company.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by a key executive.
Key Dates
| Date | Description |
|---|---|
| Feb 4, 2024 | Date of the Lin Family Trust |
| 04/01/2025 | Date of stock transactions (acquisition and disposal) |
| 04/11/2025 | Signature date of the report |
Keywords
Form 4, Processa Pharmaceuticals, PCSA, Patrick Lin, Stock Transaction, Beneficial Ownership, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.